COPEGUS

This page contains recent news articles, when available, and an overview of COPEGUS but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

COPEGUS (when available)

Pharmacology and use:
Ribavirin is an anti-viral drug active against a number of DNA and RNA viruses. It is a member of the nucleoside antimetabolite drugs that interfere with duplication of the viral genetic material. The drug inhibits the activity of the enzyme RNA dependent RNA polymerase, due to it's resemblence to building blocks of the RNA molecules. The oral form is used in the treatment of hepatitis C, in combination with interferon drugs. The aerosol form is used to treat respiratory syncytial virus-related diseases in children. The primary serious adverse effect of ribavirin is hemolytic anemia, which may worsen preexisting cardiac disease. For the treatment of chronic hepatitis C and for respiratory syncytial virus (RSV)

Mechanism Of Action:
Ribavirin is readily phosphorylated intracellularly by adenosine kinase to ribavirin mono-, di-, and triphosphate metabolites. Ribavirin triphosphate (RTP) is a potent competitive inhibitor of inosine monophosphate (IMP) dehydrogenase, viral RNA polymerase and messenger RNA (mRNA) guanylyltransferase (viral). Guanylyltranserase inhibition stops the capping of mRNA . These diverse effects result in a marked reduction of intracellular guanosine triphosphate (GTP) pools and inhibition of viral RNA and protein synthesis. Ribavirin is also incorporated into the viral genome causing lethal mutagenesis and a subsequent decrease in specific viral infectivity.

News Articles on Ribavirin

Pharmasset to Present at the Natixis Bleichroeder Hidden Gems ...  -  Oct 8, 2008
R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic Earthtimes (press release),

Richard ET Smith, Ph.D. Joins Pharmasset as Vice President of ...  -  Oct 6, 2008
R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic SYS-CON Media,

Pharmasset to Present at the JMP Securities Healthcare Focus ...  -  Oct 1, 2008
R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic Earthtimes (press release),

InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN ...  -  Sep 24, 2008
...(HCV) NS3 protease inhibitor, currently in a Phase 1b clinical trial in combination with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin). Earthtimes (press release),

From the analyst's couch: Hepatitis C therapies  -  Oct 3, 2008
Marketed ribavirin includes Rebetol (Schering–Plough), Copegus (Roche) and various generic versions. The overall clinical success rate, referred to as Nature.com (subscription),

Medivir: Phase IIa data on TMC435350 in patients with hepatitis C ...  -  Sep 24, 2008
...to Standard of Care (SoC) treatment peginterferon alpha-2a (Pegasys®) and ribavirin (Copegus®), which is then continued for another 20 or 44 weeks. Earthtimes (press release),

Fas IIa data från hepatit C-patienter behandlade med TMC435350 ...  -  Sep 24, 2008
...en gång per dag under fyra veckor (28 dagar) som tillägg till standardbehandling (SoC) med peginterferon alfa-2a (Pegasys®) och ribavirin (Copegus®). Newsdesk (pressmeddelande),

Pharmasset to Present at the Upcoming Citibank and Morgan Stanley ...  -  Sep 5, 2008
R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic MarketWatch

InterMune Earns Development Milestone in HCV Protease Inhibitor ...  -  Sep 2, 2008
In late May 2008 , InterMune initiated a 14-day study of ITMN-191 in combination with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin). Earthtimes (press release),

Pharmasset Reports Preliminary Results of a 4-week Proof-of ...  -  Sep 8, 2008
90% of genotype 2 or 3 patients achieve undetectable HCV RNA levels following 4 weeks of treatment with R7128 1500mg BID with Pegasys(R) plus Copegus(R) PR Newswire (press release),

InterMune earns $15 mln development milestone in hepatitis C virus ...  -  Sep 2, 2008
...for the hepatitis C virus NS3 protease inhibitor compound ITMN-191, currently in a Phase 1b clinical trial in combination with Pegasys and Copegus. RTT News,

Pharmasset Reports Preliminary Results of a 4-week Proof-of ...  -  Sep 8, 2008
Pegasys(R) (pegylated interferon) plus Copegus(R) (ribavirin) in 20 patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3 who had PipelineReview.com (press release),

InterMune Inc receives development milestone payment for HCV ...  -  Sep 3, 2008
The compound is currently in a Phase 1b clinical trial in combination with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin). Trading Markets (press release),

Other News To Note  -  Sep 2, 2008
...currently in a Phase Ib trial in combination with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin) as a treatment for the hepatitis C virus. TMCnet

Market Report -- In Play (VRUS)  -  Sep 8, 2008
Pegasys plus Copegus in 20 patients chronically infected with hepatitis C virus genotype 2 or 3 who had not achieved a Sustained Viral Response with MSN Money

ITMN: To Receive $15M Development Milestone Under Collaboration w ...  -  Sep 2, 2008
...currently in a Phase 1b clinical trial in combination with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin). Under the terms of their 2006 Trading Markets (press release),

Pharmasset Reports Positive Results From Phase I HCV Combination ...  -  07 Aug 2008
...in combination with the standard of care, Pegasys plus Copegus, in 31 treatment-naive patients chronically infected with hepatitis C virus genotype 1. RedOrbit,

UPDATE 1-Pharmasset: hepatitis C drug positive in early stage  -  Aug 5, 2008
The drug, R7128, was being tested for a 1000 milligram, twice daily dose in combination with two current hepatitis C therapies, Pegasys and Copegus, Reuters

Pharmasset Reports Preliminary Results of a 4-week Combination ...  -  Aug 5, 2008
R7128, an oral treatment for chronic HCV infection, is in a Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic CNNMoney.com (press release)

Pharmasset Announces Consummation of $24.18 Million Registered ...  -  Jul 23, 2008
R7128, an oral treatment for chronic HCV infection, is in a Phase 1/2 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic FOXBusiness

European Approval For Roche's Pegasys Personalises Treatment For A ...  -  Jul 20, 2008
Roche announced that the European Commission has approved a shortened, 16-week course of treatment with Pegasys (peginterferon alfa-2a (40 KD)) plus Copegus Medical News Today (press release),

InterMune Reports Second Quarter 2008 Financial Results and ...  -  Jul 31, 2008
Announced on May 29 the initiation of a 14-day study of ITMN-191 in combination with Pegasys(R) (pegylated interferon alpha-2a) and Copegus(R) (ribavirin). CNNMoney.com (press release)

VRUS: Announces Preliminary Results of Third Cohort in Ph I Trial ...  -  Aug 5, 2008
...(pegylated interferon) plus Copegus(R) (ribavirin), in 31 treatment-naive patients chronically infected with hepatitis C virus (HCV) genotype 1. Trading Markets (press release),

Roche posts very good results: strong market outperformance ...  -  Jul 20, 2008
Sales by Chugai in Japan were stable (versus 7% market growth), with the launches of Avastin, Tarceva and combined Pegasys–Copegus compensating for Business-News,

Pharmasset Announces $25.9 Million Registered Direct Offering of ...  -  Jul 15, 2008
R7128, an oral treatment for chronic HCV infection, is in a Phase 1/2 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic PharmaLive.com (press release),

Roche mit sehr gutem Ergebnis: Wachstum deutlich über dem Markt ...  -  Jul 20, 2008
Durch Markteinführungen von Avastin, Tarceva und der Kombinationsbehandlung mit Pegasys plus Copegus konnten diese Einflüsse kompensiert werden. Business-News,

Roche présente bon bilan à six mois  -  Jul 21, 2008
En juin, les autorités de l’UE ont donné leur approbation à un cycle thérapeutique abrégé avec Pegasys et Copegus (ribavirine) chez les patients avec webjournal.ch,

Roche abandona la investigación en el campo del VIH  -  Jul 16, 2008
La combinación de fármacos para tratar la hepatitis C que comercializa -el interferón pegilado (Pegasys®) y la ribavirina (Copegus®)- ha supuesto una mejora Periodista Digital,

Pharmasset Joins Russell 3000 Index  -  Jul 1, 2008
R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic PharmaLive.com (press release),

Pharmasset Receives Notice of Allowance  -  Jun 26, 2008
Cohort 3 will continue dose-exploration with administration of R7128 1000mg twice-daily (BID) with Pegasys plus Copegus in treatment-naive patients with HCV Earthtimes (press release),

UPDATE 1-EU clears shorter course of Roche hepatitis C drug  -  Jun 26, 2008
...it had received European Union approval for a shortened treatment course for Pegasys in combination with Copegus for certain hepatitis C patients. Reuters

European Approval for Roche's Pegasys Personalises Treatment for a ...  -  Jun 25, 2008
This shorter treatment duration with Pegasys/Copegus will provide patients with the full benefits of therapy while reducing unnecessary drug exposure. ITNews,

Pharmasset receives notice of allowance for anti-HCV drug  -  Jun 26, 2008
Results showed that 85% of patients receiving R7128 1500mg twice daily with Pegasys plus Copegus for 4 weeks achieved undetectable HCV RNA levels with RTT News,

European Commission Approves Shortened Treatment With ...  -  Jun 26, 2008
16-week course of treatment with peginterferon alfa-2a (40 KD) (Pegasys) plus ribavirin (Copegus) for certain hepatitis C patients. DG News

European approval for shortened course of Roche drug  -  Jun 26, 2008
The drug is approved for use with the medicine Copegus as a 16-week course in patients with particular strains of chronic hepatitis C who have low virus Hays Pharma,

Pharmasset to Present at the Needham & Co. Biotechnology and ...  -  Jun 5, 2008
R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic PharmaLive.com (press release),

Swiss stocks - Factors to watch on June 26  -  Jun 25, 2008
Roche said on Thursday it had received European approval for a shortened treatment course for Pegasys in combination with Copegus for certain hepatitis C Reuters

Swiss stocks - Factors to watch on June 26  -  Jun 25, 2008
Roche said on Thursday it had received European approval for a shortened treatment course for Pegasys in combination with Copegus for certain hepatitis C Reuters India,

Chelsea Therapeutics Appoints Joseph Oliveto as Vice President ...  -  Jun 17, 2008
...of multiple NDA filings, developed comprehensive launch programs, including those for both Pegasys and CoPegus, and closed multiple licensing deals. TMCnet

Call for action now to cut Hep C burden  -  Jun 27, 2008
THE number of hepatitis C patients receiving treatment needs to double within five years just to stop the existing flow of cases of liver cirrhosis and The Australian,

PEGASYS(R)/COPEGUS(R) Show Benefit in Hard-to-Treat Latino ...  -  May 19, 2008
The results showed that 33.5 percent (90/269) of the Latino patients achieved sustained virological response (SVR) when treated with PEGASYS plus COPEGUS. FOXBusiness

Hepatitis C Latino Patients Benefit From Pegasys Copegus  -  May 21, 2008
The results showed PEGASYS (peginterferon alfa-2a) in combination with COPEGUS (ribavirin) was beneficial in this hard-to-treat population. eMaxHealth.com,

Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the ...  -  May 14, 2008
Cohort 4 will evaluate R7128 1500mg BID administered in combination with Pegasys plus Copegus in treatment-experienced patients with genotypes 2 or 3 who FOXBusiness

InterMune Announces Start of 14-Day Triple Combination Study of ...  -  May 29, 2008
...in combination with Pegasys(R) (pegylated interferon alpha-2a) and Copegus(R) (ribavirin) in treatment-naive patients infected with chronic hepatitis C PharmaLive.com (press release),

Pharmasset Reports Financial Results for Quarter Ended March 31, 2008  -  May 15, 2008
We and Roche are currently focused on planning a global 12-week Phase 2b combination study of R7128 with Pegasys plus Copegus. MSN Money

Romark Completes Enrollment in Phase II Hepatitis Combination ...  -  May 21, 2008
Pegasys and Copegus are being provided under a collaborative agreement between Romark and Hoffmann-La Roche. Marc Ayers, CEO of Romark, said: "We believe RedOrbit,

Pharmasset Selected to Join the NASDAQ Biotechnology Index  -  May 12, 2008
R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic Earthtimes (press release),

Roche Study Shows Treatment Benefits Latino Patients With Hepatitis C  -  May 21, 2008
Latino patients were associated with sustained virological response (SVR) when treated with Pegasys (peginterferon alfa-2a) plus Copegus (ribavirin). FDA news (subscription),

Pharmasset Nominates PSI-7851 as a Lead Development Candidate for ...  -  May 19, 2008
R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic FOXBusiness

Market Report -- In Play (WIRES)  -  May 14, 2008
Pharmasset (VRUS) has commenced dosing two additional cohorts of a 4-week Phase 1 study of R7128 in combination with Pegasys plus Copegus in both MSN Money

Brand Names/Synonyms:
COPEGUS is also known by the following brand names and/or synonymsBiopolymers; Copegus; DRG-0028; HSDB 6513; ICN 1229; ICN-1229; RBV; RIBAV; RTC; RTCA; RTP; Rebetol; Rebetron; Rebretron; Ribamide; Ribamidil; Ribamidyl; Ribasphere; Ribavirin; Ribavirin Capsules; Ribavirin Triphosphate; Ribavirin [Usan:Inn]; Ribavirin-Tp; Ribavirina [Inn-Spanish]; Ribavirine; Ribavirine [Inn-French]; Ribavirinum [Inn-Latin]; Tribavirin; Varazid; Vilona; Viramid; Virazid; Virazole; Virazole 5'-Triphosphate

Drug Category:
COPEGUS is categorized under the following by the FDA: Antiviral; ATC:J05AB04

Dosage Forms:
Inhalation solution, Tablets

Absorption:
Ribavirin was rapidly and extensively absorbed following oral administration. However, due to first-pass metabolism, the absolute bioavailability averaged 64% (44%).

Interactions:
[an error occurred while processing this directive]

Chemical IUPAC Name:
1-[3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-1,2,4-triazole-3-carboxamide

:

Web health.mongabay.com

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.